Nothing Special   »   [go: up one dir, main page]

DE69933218D1 - Methode zur behandlung von krankheiten durch veränderung der wechselwirkung zwischen natural killer rezeptoren auf t-zellen mit ihren jeweiligen liganden - Google Patents

Methode zur behandlung von krankheiten durch veränderung der wechselwirkung zwischen natural killer rezeptoren auf t-zellen mit ihren jeweiligen liganden

Info

Publication number
DE69933218D1
DE69933218D1 DE69933218T DE69933218T DE69933218D1 DE 69933218 D1 DE69933218 D1 DE 69933218D1 DE 69933218 T DE69933218 T DE 69933218T DE 69933218 T DE69933218 T DE 69933218T DE 69933218 D1 DE69933218 D1 DE 69933218D1
Authority
DE
Germany
Prior art keywords
cells
natural killer
methods
illnesses
interaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69933218T
Other languages
English (en)
Inventor
Brian J Nickoloff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69933218D1 publication Critical patent/DE69933218D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DE69933218T 1998-07-09 1999-06-28 Methode zur behandlung von krankheiten durch veränderung der wechselwirkung zwischen natural killer rezeptoren auf t-zellen mit ihren jeweiligen liganden Expired - Lifetime DE69933218D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9215198P 1998-07-09 1998-07-09
US10989498P 1998-11-25 1998-11-25
PCT/US1999/014549 WO2000002923A1 (en) 1998-07-09 1999-06-28 Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands

Publications (1)

Publication Number Publication Date
DE69933218D1 true DE69933218D1 (de) 2006-10-26

Family

ID=26785331

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69933218T Expired - Lifetime DE69933218D1 (de) 1998-07-09 1999-06-28 Methode zur behandlung von krankheiten durch veränderung der wechselwirkung zwischen natural killer rezeptoren auf t-zellen mit ihren jeweiligen liganden

Country Status (6)

Country Link
EP (1) EP1095062B1 (de)
JP (1) JP2003524146A (de)
AT (1) ATE339452T1 (de)
AU (2) AU4837499A (de)
DE (1) DE69933218D1 (de)
WO (2) WO2000002923A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1300681A4 (de) * 2000-07-12 2004-07-14 Orient Cancer Therapy Co Ltd Mittel zum bestimmen der immunfunktionen
EP1372668B1 (de) 2001-03-26 2011-12-07 Dana-Farber Cancer Institute, Inc. Verfahren zur abschwächung von reaktionen auf hautreizende mittel
US8084020B2 (en) * 2002-05-01 2011-12-27 Beth Israel Deaconess Medical Center Use of anti-CD1 antibodies for the modulation of immune responses
US7666411B2 (en) 2002-06-14 2010-02-23 The United States Of America As Represented By The Department Of Health And Human Services Methods of treating and preventing colitis involving IL-13 and NK-T cells
AU2003266313B2 (en) * 2002-08-27 2009-10-22 Societe Des Produits Nestle S.A. Preventing or treating epithelial tissue damage or hair loss
DE10261223A1 (de) * 2002-12-20 2004-07-08 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen
WO2004093907A2 (en) * 2003-04-23 2004-11-04 Tomoaki Hoshino Therapeutic agents for treating dermatitis, alopecia and itching and transgenic animals for evaluating such therapeutic agents
US20050069546A1 (en) * 2003-09-30 2005-03-31 Yaron Ilan Educated NKT cells and their uses in the treatment of immune-related disorders
EP1566439A1 (de) * 2004-02-20 2005-08-24 Nestec S.A. Prophylaxe oder Behandlung von Obesitas
JP4948418B2 (ja) 2004-11-02 2012-06-06 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ Ｎｋｔ細胞を抑制するための方法
CN104829720B (zh) 2005-01-06 2019-01-01 诺和诺德公司 Kir结合剂和使用其的方法
WO2006113614A2 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Service National Institutes Of Health Methods of treating and preventing inflammatory bowel disease involving il-13 and nkt cells
WO2007042573A2 (en) * 2005-10-14 2007-04-19 Innate Pharma Compositions and methods for treating proliferative disorders
CN104144700B (zh) * 2011-10-14 2016-10-19 特瓦制药澳大利亚私人有限公司 抗CD1d的抗体
US12018080B2 (en) * 2017-11-13 2024-06-25 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185430A (en) * 1987-10-16 1993-02-09 University Of Georgia Research Foundation, Inc. Antigen recognized by natural killer and non-specific cytotoxic cells
US5028424A (en) * 1987-10-16 1991-07-02 University Of Georgia Research Foundation Antibodies to receptor and antigen for natural killer and non-specific cytotoxic cells
AU1908395A (en) * 1994-01-28 1995-08-15 Board Of Trustees Of The Leland Stanford Junior University Antibodies to mammalian natural killer antigens and uses

Also Published As

Publication number Publication date
EP1095062A4 (de) 2004-03-24
JP2003524146A (ja) 2003-08-12
ATE339452T1 (de) 2006-10-15
AU4837499A (en) 2000-02-01
AU5092699A (en) 2000-02-01
EP1095062A1 (de) 2001-05-02
EP1095062B1 (de) 2006-09-13
WO2000002923A1 (en) 2000-01-20
WO2000002583A1 (en) 2000-01-20

Similar Documents

Publication Publication Date Title
DE69933218D1 (de) Methode zur behandlung von krankheiten durch veränderung der wechselwirkung zwischen natural killer rezeptoren auf t-zellen mit ihren jeweiligen liganden
DE60031456D1 (de) Rekombinante alpha-l-iduronisase, deren herstellungs- und aufreinigungsverfahren, und behandlung von durch diese hervorgerufene mangelerkrankungen
Kakiuchi et al. Cyclic 3′, 5′-nucleotide phosphodiesterase, IV. Two enzymes with different properties from brain
ATE281840T1 (de) Behandlung von diarrhoe
ATE403680T1 (de) Herstellung tetravalenter antikörper
ATE373078T1 (de) Gleichzeitige stimulation und konzentration von zellen
DK1446162T3 (da) Kombinationsmotiv-immunstimulatoriske oligonukleotider med forbedret aktivitet
DE60233805D1 (de) Zusammensetzungen und verfahren zur isolierung, vermehrung und differenzierung nicht-embryonale menschlicher stammzellen und deren verwendungen
ATE266417T1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
MXPA03010911A (es) Anticuerpos contra ngf para el tratamiento de varios desordenes.
HUP9901874A2 (hu) Humán TNFalfa-t kötő antitestek
WO2003024472A3 (en) Prolactin induced increase in neutral stem cell numbers and therapeutical use thereof
ATE202487T1 (de) Mono- oder polyfunktionelle konjugate von polylysine
DE69939312D1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
DE60230774D1 (de) Isolierung von nervenstammzellen unter verwendung von gangliosiden und anderen oberflächenmarkern
DE69737996D1 (de) Methoden zur herstellung von nukleotidintegrasen
WO1999058691A3 (en) Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
DE69629436D1 (de) Wirkungen auf der endothelauskleidung und behandlung von vasospastischen erkrankungen
WO2001042784A3 (en) Methods for screening compounds active on neurons
ATE180277T1 (de) Zur behandlung von tumoren und hiv-infektionen nützliches pflanzliches protein
DE60027127D1 (de) Verwendung von Polyaminosäurederivaten zur Behandlung von Seborrhoe und verwandten Hautstörungen
Olupona A PHENOMENOLOGICAL/ANTHROPOLOGICAL ANALYSIS OF THE RELIGION OF THE ONDO-YORUBA OF NIGERIA.
ATE159032T1 (de) Anti-hiv protein, tap-29, aus trichosanthes, seine kodierende dna und therapeutischen anwendungen
Hasan et al. Partial purification of topoisomerase IB from serum of diabetic patients and study it's kinetic properties and molecular weight
DE60017136D1 (de) Behandlung von angiogenese-abhängigen erkrankungen mit dextrinsulphat

Legal Events

Date Code Title Description
8332 No legal effect for de